Topotecan given as a 21-day infusion in the treatment of advanced ovarian cancer.

Gore, M; Rustin, G; Schüller, J; Lane, S R; Hearn, S; Beckman, R A; Ross, G

Gore, M; Rustin, G; Schüller, J; Lane, S R; Hearn, S; Beckman, R A; Ross, G.

Affiliation

Gore M; Royal Marsden Hospital, Fulham Rd, London, SW3 6JJ, UK.

Br J Cancer ; 84(8): 1043-6, 2001 Apr 20.

Article in En | MEDLINE | ID: mdl-11308251

Subject(s)

Antineoplastic Agents/therapeutic use; Ovarian Neoplasms/drug therapy; Topotecan/therapeutic use; Abdominal Pain/chemically induced; Adult; Aged; Alopecia/chemically induced; Antineoplastic Agents/adverse effects; Diarrhea/chemically induced; Fatigue/chemically induced; Female; Hematologic Diseases/chemically induced; Humans; Infusions, Intravenous; Middle Aged; Nausea/chemically induced; Ovarian Neoplasms/mortality; Ovarian Neoplasms/pathology; Survival Analysis; Survival Rate; Time Factors; Topotecan/adverse effects; Treatment Outcome; Vomiting/chemically induced

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Ovarian Neoplasms / Topotecan / Antineoplastic Agents Limits: Adult / Aged / Female / Humans / Middle aged Language: En Journal: Br J Cancer Year: 2001 Type: Article Affiliation country: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google